ORIC Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de ORIC Pharmaceuticals es Jacob Chacko , nombrado en May 2018, tiene una permanencia de 6.5 años. compensación anual total es $3.15M, compuesta por 18.9% salario y 81.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.03% de las acciones de la empresa, por valor de €6.86M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 4.6 años, respectivamente.

Información clave

Jacob Chacko

Chief Executive Officer (CEO)

US$3.2m

Compensación total

Porcentaje del salario del CEO	18.9%
Permanencia del CEO	6.5yrs
Participación del CEO	1.0%
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jacob Chacko en comparación con los beneficios de ORIC Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$120m
Jun 30 2024	n/a	n/a	-US$111m
Mar 31 2024	n/a	n/a	-US$102m
Dec 31 2023	US$3m	US$596k	-US$101m
Sep 30 2023	n/a	n/a	-US$93m
Jun 30 2023	n/a	n/a	-US$93m
Mar 31 2023	n/a	n/a	-US$90m
Dec 31 2022	US$4m	US$572k	-US$89m
Sep 30 2022	n/a	n/a	-US$91m
Jun 30 2022	n/a	n/a	-US$85m
Mar 31 2022	n/a	n/a	-US$85m
Dec 31 2021	US$7m	US$536k	-US$79m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$91m
Mar 31 2021	n/a	n/a	-US$81m
Dec 31 2020	US$6m	US$489k	-US$74m
Sep 30 2020	n/a	n/a	-US$54m
Jun 30 2020	n/a	n/a	-US$35m
Mar 31 2020	n/a	n/a	-US$30m
Dec 31 2019	US$672k	US$456k	-US$27m
Dec 31 2018	US$2m	US$290k	-US$21m

Compensación vs. Mercado: La compensación total de Jacob($USD3.15M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.44M).

Compensación vs. Ingresos: La compensación de Jacob ha sido consistente con los resultados de la empresa en el último año.

CEO

Jacob Chacko (45 yo)

6.5yrs

Permanencia

US$3,153,083

Compensación

Dr. Jacob M. Chacko, M.D., MBA, has been Chief Executive Officer and Director of ORIC Pharmaceuticals, Inc. since May 2018 and has been its President since May 2019. Dr. Chacko joined the ORIC Pharmaceutic...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Richard Heyman	Co-Founder	9.7yrs	US$186.87k	0.32% € 2.2m
Jacob Chacko	President	6.5yrs	US$3.15m	1.03% € 6.9m
Dominic Piscitelli	Chief Financial Officer	5.2yrs	US$1.45m	0.12% € 789.6k
Pratik Multani	Chief Medical Officer	6.2yrs	US$1.51m	0.034% € 224.3k
Charles Sawyers	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Scott Lowe	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Lori Friedman	Chief Scientific Officer	5.3yrs	sin datos	sin datos
Christian Kuhlen	General Counsel	4.6yrs	sin datos	sin datos
Daniel Iazzetti	VP & Head of People	2.2yrs	sin datos	sin datos
Edna Chow Maneval	Senior Vice President of Clinical Development	5.7yrs	sin datos	sin datos
Matthew Panuwat	Chief Business Officer	6yrs	sin datos	sin datos
Keith Lui	Senior VP of Commercial & Medical Affairs	less than a year	sin datos	sin datos

5.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4TZ es experimentado (5.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Richard Heyman	Co-Founder	9.7yrs	US$186.87k	0.32% € 2.2m
Jacob Chacko	President	6.5yrs	US$3.15m	1.03% € 6.9m
Charles Sawyers	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Scott Lowe	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Laurence Lasky	Member of Scientific Advisory Board	no data	sin datos	sin datos
Angie You	Independent Director	3yrs	US$140.37k	0% € 0
Lori Kunkel	Independent Director	4.4yrs	US$133.87k	0.029% € 193.1k
Mardi Dier	Independent Director	4.8yrs	US$147.87k	0% € 0
Steven Hoerter	Independent Director	3.3yrs	US$141.37k	0% € 0

4.6yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 4TZ se considera experimentada (4.6 años de antigüedad promedio).

ORIC Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

ORIC Pharmaceuticals, Inc. Appoints Keith Lui as Senior Vice President of Commercial and Medical Affairs

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

President recently bought €1.2m worth of stock

Recent updates

New major risk - Revenue and earnings growth

ORIC Pharmaceuticals, Inc. Appoints Keith Lui as Senior Vice President of Commercial and Medical Affairs

New major risk - Share price stability

ORIC Pharmaceuticals, Inc. Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

ORIC Pharmaceuticals, Inc. announced that it has received $125 million in funding from Viking Global Investors LP, Commodore Capital LP, Frazier Management, L.L.C., Frazier Life Sciences Management, LP, VR Adviser, LLC, Nextech Invest Ltd.

ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944

ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations

New major risk - Share price stability

ORIC Pharmaceuticals, Inc. announced that it has received $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals, Inc. announced that it expects to receive $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

ORIC Pharmaceuticals, Inc. Presents Preclinical Data Demonstrating Oric-533 as A Potential Best-In-Class CD73 Inhibitor at the 64th American Society of Hematology Annual Meeting

ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) dropped from Russell 2000 Dynamic Index

President recently bought €1.2m worth of stock

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

ORIC Pharmaceuticals, Inc. Provides Corporate Update and Highlights Key Upcoming Milestones

ORIC Pharmaceuticals, Inc. Presents Data Supporting the Therapeutic Potential of ORIC3 in Multiple Myeloma At the American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

ORIC Pharmaceuticals, Inc. Announces Initial Data from an Ongoing Phase 1B Study Evaluating Oric-10

Independent Director & Member of Scientific Advisory Board Richard Scheller has left the company

ORIC Pharmaceuticals, Inc. Reports Initial Clinical Data Being Presented at ASCO from Phase 1B Trial of ORIC-101 in Combination with Nab-Paclitaxel

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

ORIC Pharmaceuticals, Inc. Provides Corporate Update

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

New 90-day high: €30.20

New 90-day high: €22.80

ORIC Pharmaceuticals, Inc. Enters into an Exclusive License Agreement with Voronoi, Inc

New 90-day low: €17.00

ORIC Pharmaceuticals, Inc. announced that it expects to receive funding from a group of investors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad